This morning, we published a new Quarterly Update on Bioniche Life Sciences Inc. (BNC-TSX; BNC-ASX). Bioniche is a Canadian company providing innovative research, technologies, and therapeutics for human and animal health worldwide. Bioniche is structured in three global business units: (1) Bioniche Therapeutics (Human Health); (2) Bioniche Animal Health; and (3) Bioniche Food Safety. The following key areas, among many other of Bioniche’s business initiatives, are profiled in this newest update, which is available free of charge on our website.
- Bioniche’s most advanced Human Health product candidate is Urocidin, a treatment for non-muscle-invasive bladder cancer that is in two Phase III clinical trials through a license agreement with Endo Pharmaceuticals (ENDP-NASDAQ). As of February 2011, Urocidin™ treatment in Bioniche’s first Phase III trial was associated with overall disease-free survival of 25% at one year, which the Company believes is highly favorable given the trial’s strict enrollment criteria and the safety profile of Urocidin™.
- With a portfolio of over 60 products, Bioniche Animal Health develops products that enhance reproductive performance in animals and reduce the animal health industry’s reliance on antibiotics. A lead Animal Health product is Folltropin-V, a reproductive hormone with an estimated 70% market share that induces superovulation in cattle and sheep. Over the past six to eight months, Bioniche has entered into a number of strategic agreements for its various animal health programs, including an exclusive three-year supply agreement with Angus Australia via Bayer Animal Health (part of Bayer Australia Ltd), the exclusive distributor of Bioniche’s cattle reproduction products in Australia.
- Bioniche Food Safety develops veterinary biopharmaceuticals to improve the safety of human food and water supplies. Its Econiche cattle vaccine reduces the level of E. coli O157:H7 shed by cattle, thus minimizing the risk of human illness from contaminated food or water. Bioniche expects to complete the scale-up of its Econiche production facility in Belleville, supported with C$25 million in government funding, by April 2011. The facility may produce over 40 million doses per year.
- In late 2010, Bioniche was ranked number 14 among the Top 50 Best Small and Medium Employers in Canada.
To navigate directly to a PDF of the report, please click here.